V

Vapotherm Inc
F:VA21

Watchlist Manager
Vapotherm Inc
F:VA21
Watchlist
Price: 2.976 EUR
Market Cap: €137.6m

EV/OCF

-10.7
Current
5%
More Expensive
vs 3-y median of -10.1

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-10.7
=
Enterprise Value
€220.2m
/
Operating Cash Flow
$-24.3m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
-10.7
=
Enterprise Value
€220.2m
/
Operating Cash Flow
$-24.3m

Valuation Scenarios

Vapotherm Inc is trading above its industry average

If EV/OCF returns to its Industry Average (18.7), the stock would be worth €-5.2 (275% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-275%
Maximum Upside
No Upside Scenarios
Average Downside
265%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple -10.7 €2.98
0%
Industry Average 18.7 €-5.2
-275%
Country Average 16.7 €-4.65
-256%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 9 518 companies
0th percentile
-10.7
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Vapotherm Inc
Glance View

Market Cap
137.6m EUR
Industry
Health Care

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.

VA21 Intrinsic Value
Not Available
V
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett